Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now

Additionally, the institution dosed the archetypal diligent successful its Phase 1 survey of REC-4539, a reversible LSD1 inhibitor designed to debar the platelet toxicity communal successful akin treatments. These milestones underscore the company’s quality to usage its “full stack” OS to rapidly construe biologic insights into differentiated objective candidates.

The company’s precocious programs besides reached captious inflection points, peculiarly REC-4881 for familial adenomatous polyposis/FAP. Following affirmative Phase 2 information that showed a 53% simplification successful polyp burden, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) initiated engagement with the FDA to specify a imaginable registrational pathway, with a ceremonial update expected successful H2 2026. The institution continues to beforehand large-scale “maps of biology” with Roche and Genentech, utilizing implicit 1 trillion internally manufactured neuronal cells to place caller targets successful oncology and immunology.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is simply a Utah-based clinical-stage biotech institution that specializes successful the decoding of biology and chemistry. The institution develops its solutions by integrating technological advancements successful AI and ML to accelerate cause discovery.

While we admit the imaginable of RXRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.